Showing 15 posts of 382 posts found.


Novo’s semaglutide injection and tablets get expanded FDA approval for type 2 diabetes with established CVD

January 17, 2020
Medical Communications, Sales and Marketing FDA, Novo Nordisk, Ozempic, cardiovascular disease, diabetes, pharma

Novo Nordisk has seen label expansions approved from the FDA for both its glucagon-like peptide-1 (GLP-1) analogue injection Ozempic (once-weekly …


Diabetes drug could increase stem cells in the womb to treat recurrent miscarriage

January 9, 2020
Business Services Stem cells, diabetes, insulin, miscarraiges, pregnancy

A study led by the University of Warwick found that sitagliptin, a diabetes drug, could be used to treat recurrent …

Novo Nordisk to offer US patient’s in immediate need free insulin

January 3, 2020
Medical Communications Novo, Novo Nordisk, Type 1 diabetes, diabetes, insulin, type 2 diabetes

Novo Nordisk said it would offer free, one-time supply of insulin to those in need, amidst rising insulin prices. Novo …


FDA approves artificial pancreas developed by the University of Virginia

January 2, 2020
Business Services, Medical Communications FDA, Pancreas, Type 1 diabetes, diabetes, insulin, type 2 diabetes

The FDA has approved an artificial pancreas system based on technology from the University of Virginia’s Center for Diabetes Technology. …

Sanofi to move away from diabetes and cardiovascular, as company shakeup continues

December 10, 2019
Manufacturing and Production ASH 19, Sanofi, Sanofi Diabetes, Sanofi Insulin, diabetes, insulin

Sanofi has said it will stop investment and research into creating new diabetes and cardiovascular drugs, as part of the …


South Korea jails executives for their role in Samsung Biologics fraud

December 10, 2019
Manufacturing and Production Samsung phones, Sanofi, Sanofi Diabetes, South Korea Healthcare System, South Korea Samsung, diabetes, inhaled insulin, insulin, south korea

Three executives of Samsung Electronics have been sentenced to jail for their role in committing fraud at its biotech affiliate …


FDA investigating if carcinogen NDMA is in diabetes drug

December 6, 2019
Medical Communications FDA, Health Canada, MDMA, NDMA, carcinogen, diabetes

The FDA is looking into if the diabetes drug metformin has unsafe levels of a cancer-causing chemical. This comes after …


AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes

November 15, 2019
Medical Communications, Sales and Marketing AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …


New report reveals shocking knowledge gaps around type 2 diabetes risk factors

November 14, 2019
Medical Communications, Research and Development Merck KGaA, diabetes, pharma, type 2 diabetes

A new report released on World Diabetes Day has shone a light on a startling lack of knowledge surrounding type …

Promising Phase 3 data for Sanofi’s Toujeo secures CHMP recommendation of label expansion in type 1 diabetes

November 4, 2019
Research and Development, Sales and Marketing EU, Sanofi, Type 1 diabetes, diabetes, pharma, toujeo

Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …


Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes

September 20, 2019
Medical Communications, Research and Development Novo Nordisk, Tresiba, diabetes, pharma

Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for …

Sanofi’s Troujeo beats insulin degludec in head-to-head study in type 2 diabetes

September 19, 2019
Research and Development Sanofi, Troujeo, diabetes, insulin degludec, pharma

Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from …

Sanofi ends partnership with Lexicon after release of Phase 3 data

July 29, 2019
Sales and Marketing Lexicon, Sanofi, Zynquista, diabetes, pharma

French firm Sanofi has said it is ending its partnership with Texas-based firm Lexicon Pharmaceuticals over the development of diabetes …


Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection

July 25, 2019
Sales and Marketing Baqsimi, Eli Lilly, FDA, US, diabetes, pharma

Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …


AstraZeneca’s Farxiga fails to get FDA approval for patients with Type 1 diabetes

July 15, 2019
Sales and Marketing AstraZeneca, EMA, FDA, US, diabetes, farxiga

The FDA had said it will not approve AstraZeneca’s diabetes drug Farxiga for use as a supplement to insulin in …

Latest content